Biogen Inc. Share Price Xetra

Equities

IDP

US09062X1037

Pharmaceuticals

Market Closed - Xetra 09:05:33 15/05/2024 pm IST After market 11:48:25 pm
214.8 EUR +4.27% Intraday chart for Biogen Inc. 217 +1.02%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 9.52B 8.75B 794B Sales 2025 * 9.55B 8.78B 796B Capitalization 33.03B 30.36B 2,754B
Net income 2024 * 1.9B 1.74B 158B Net income 2025 * 2.21B 2.03B 184B EV / Sales 2024 * 3.79 x
Net Debt 2024 * 3.01B 2.77B 251B Net Debt 2025 * 536M 492M 44.68B EV / Sales 2025 * 3.52 x
P/E ratio 2024 *
17.5 x
P/E ratio 2025 *
15.2 x
Employees 7,570
Yield 2024 *
-
Yield 2025 *
-
Free-Float 85.81%
More Fundamentals * Assessed data
Dynamic Chart
1 day+5.32%
1 week+4.78%
Current month+5.71%
1 month+14.65%
3 months+3.67%
6 months+1.70%
Current year-8.52%
More quotes
1 week
203.30
Extreme 203.3
214.80
1 month
177.65
Extreme 177.65
214.80
Current year
177.65
Extreme 177.65
245.60
1 year
177.65
Extreme 177.65
309.80
3 years
174.26
Extreme 174.26
351.70
5 years
174.26
Extreme 174.26
351.70
10 years
174.26
Extreme 174.26
447.80
More quotes
Managers TitleAgeSince
Chief Executive Officer 64 14/22/14
Director of Finance/CFO 60 15/20/15
Chief Operating Officer - 01/15/01
Members of the board TitleAgeSince
Director/Board Member 75 01/10/01
Director/Board Member 70 19/19/19
Chairman 64 03/10/03
More insiders
Date Price Change Volume
15/24/15 214.8 +4.27% 2 646
14/24/14 206 -0.68% 203
13/24/13 207.4 +0.44% 125
10/24/10 206.5 +1.23% 262
09/24/09 204 -0.49% 308

Delayed Quote Xetra, May 15, 2024 at 09:05 pm IST

More quotes
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows: - sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.; - royalties (17,2%) ; - other (9,1%): primarily revenues from partnership agreements.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
226.9 USD
Average target price
285.9 USD
Spread / Average Target
+26.02%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW